LIBTAYO is a recombinant human immunoglobulin G4 (IgG4) monoclonal
antibody
that binds to programmed cell death 1 (PD-1)
Click to watch LIBTAYO’s mechanism of action
CSCC: cutaneous squamous cell carcinoma; PD-L1: programmed
death-ligand 1; PD-L2:
programmed death-ligand 2.
† Clinical significance is unknown.
Adapted from LIBTAYO Product Monograph1
